SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-13-001185
Filing Date
2013-04-23
Accepted
2013-04-23 11:56:14
Documents
7
Period of Report
2012-12-31

Document Format Files

Seq Description Document Type Size
1 20-F zk1312988.htm 20-F 2941733
2 EXHIBIT 4.15 exhibit_4-15.htm EX-4.15 689178
3 EXHIBIT 8.1 exhibit_8-1.htm EX-8.1 2362
4 EXHIBIT 12.1 exhibit_12-1.htm EX-12.1 9160
5 EXHIBIT 12.2 exhibit_12-2.htm EX-12.2 8865
6 EXHIBIT 13.1 exhibit_13-1.htm EX-13.1 4955
7 EXHIBIT 13.2 exhibit_13-2.htm EX-13.2 4765
  Complete submission text file 0001178913-13-001185.txt   3661996
Mailing Address 8 HARTOM ST., 3RD FLOOR, JERUSALEM L3 97775
Business Address 8 HARTOM ST., 3RD FLOOR, JERUSALEM L3 97775 972-2-5486555
BioCancell Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1211
Type: 20-F | Act: 34 | File No.: 333-179140 | Film No.: 13775690
SIC: 2834 Pharmaceutical Preparations